Based on the provided data, the forecast for cardiovascular system medicine sales in the UK shows a decreasing trend with values declining from 5.1% in 2024 to 4.2% by 2028. The year-on-year variation indicates a consistent decrease of approximately 6-7% annually. Comparing this with the past two years, the decline aligns with the recent 5-year CAGR of around -5.5% per year from 2023 onwards. This analysis reflects a steady reduction in sales volume or value of cardiovascular medicines.
Future trends to watch for include advancements in alternative treatments, increased focus on preventative care, and potential impacts of healthcare policy changes. Monitoring technological developments and regulatory shifts will be crucial in predicting further market dynamics.
